Resultado de búsqueda
La vacuna de Janssen se puede ofrecer a quienes ya hayan padecido COVID-19, pero las personas pueden optar por retrasar la vacunación por 3 meses después de la infección. ¿Se puede administrar la vacuna a las personas inmunodeprimidas?
The Janssen COVID‑19 vaccine, sold under the brand name Jcovden, is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, and its Belgian parent company Janssen Pharmaceuticals, a subsidiary of American company Johnson & Johnson.
La vacuna Johnson & Johnson contra la COVID-19 consiste en un vector de adenovirus recombinante de tipo 26 (Ad26) de replicación incompetente que expresa la proteína pico (S) del síndrome respiratorio agudo severo del coronavirus 2 (SARS-CoV-2) en una conformación estabilizada.
6 de ene. de 2022 · The Johnson & Johnson COVID-19 vaccine demonstrated a profile that showed durability of effectiveness up to 6 months for hospitalizations and ICU admissions across the study period, with a modest increase in breakthrough infections starting in month 4.
20 de ene. de 2022 · The benefits of Janssen and mRNA COVID-19 vaccination over 180 days per million fully vaccinated persons*** aged ≥18 years were assessed, including 1) COVID-19 hospitalizations prevented, based on rates during the week ending November 13, 2021 ††† and 2) age- and vaccine-specific vaccine effectiveness estimates from the ...
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use - First Single-Shot Vaccine in Fight Against Global Pandemic Data demonstrated protection against COVID-19 related hospitalization and death, across countries with different variants
Johnson & Johnson is testing a coronavirus vaccine known as JNJ-78436735 or Ad26.COV2.S. Clinical trials showed that a single dose of the vaccine had an efficacy rate of 72 percent in the...
